Enterprise AI Analysis
AI Fragmentation-Based Optimization of Sorafenib Derivatives Targeting VEGFR2 for Angiogenesis-Related Pathologies: A Structure-Based in-Silico Study
This study leverages artificial intelligence and advanced computational methods to develop optimized Sorafenib derivatives, aiming to enhance the treatment of angiogenesis-related pathologies by specifically targeting VEGFR2. It addresses the limitations of current inhibitors through structure-based drug design and in-silico validation, identifying a promising lead candidate with improved binding affinity and safety profiles.
Executive Impact & Strategic Insights
Harnessing AI in drug discovery accelerates lead optimization, reduces R&D costs, and improves therapeutic safety, driving significant competitive advantage.
AI-Optimized Derivatives Generated
Binding Affinity Improvement
Hepatotoxicity Risk Reduction
MD Simulation Validation
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Overview
Methodology
Results & Performance
Strategic Implications
Advanced VEGFR2 Inhibitor Discovery
This research presents a groundbreaking approach to optimize Sorafenib derivatives using AI-guided fragmentation and structure-based in-silico methods. By targeting VEGFR2, a key regulator in angiogenesis-related pathologies, the study aims to overcome the suboptimal pharmacokinetics and toxicity of existing inhibitors. The identified lead candidate, AI-Fragmented Derivative 7, demonstrates significantly improved binding affinity and a more favorable safety profile compared to Sorafenib, validated through rigorous molecular dynamics simulations and ADMET profiling. This highlights the transformative potential of AI in accelerating drug discovery and developing safer, more effective therapeutics.
Rigorous In-Silico Drug Design Pipeline
The methodology employed a comprehensive suite of computational techniques, starting with the retrieval and validation of VEGFR2's 3D structure (PDB ID: 3WZE). AI-driven ligand fragmentation and derivative generation, utilizing the PlayMolecule platform and CReM framework, produced twenty novel compounds. Active sites were predicted using PrankWeb, followed by molecular docking with AutoDock Vina to assess binding affinities. ADMET profiling (SwissADME, Deep-PK) and Density Functional Theory (DFT) analysis characterized pharmacokinetic and electronic properties. Finally, 500ns molecular dynamics simulations (OpenMM, AMBER) and MM/GBSA/MM/PBSA calculations validated structural stability and binding free energies, ensuring a robust selection process for the lead candidate.
Superior Binding and Safety Profile
The study successfully identified AI-Fragmented Derivative 7 (Grow) as the most promising candidate. Docking studies revealed a binding affinity of -11.7 kcal/mol, a significant improvement over Sorafenib's -10.2 kcal/mol. ADMET profiling indicated enhanced aqueous solubility and a reduced hepatotoxicity risk (DILI probability of 0.39 for Derivative 7 vs. 0.591 for Sorafenib), addressing a major limitation of current treatments. Molecular dynamics simulations confirmed the complex's stability, with consistent RMSD values and persistent hydrogen bonding. DFT analysis showed a narrower HOMO-LUMO energy gap (0.15433 a.u. vs 0.16219 a.u.), suggesting greater electronic polarizability and reactivity favorable for binding. These results collectively validate Derivative 7 as a superior in-silico lead.
Accelerating Next-Generation Therapeutics
This research provides a powerful demonstration of how AI can significantly de-risk and accelerate early-stage drug discovery. By identifying a VEGFR2 inhibitor with improved binding characteristics and a better safety profile, the study lays the groundwork for developing more effective treatments for angiogenesis-related pathologies like cancer and ocular disorders. The refined computational pipeline minimizes reliance on costly and time-consuming experimental screening, allowing for rapid iteration and optimization of drug candidates. Future work will involve experimental validation to confirm potency, selectivity, and safety, ultimately bringing advanced therapeutics closer to clinical application and impacting patient outcomes.
Optimized Binding Affinity of Lead Candidate (Derivative 7)
Enterprise Process Flow: AI-Driven Drug Design Pipeline
VEGFR2 3D Structure Retrieval & Validation
→
Sorafenib AI Fragmentation & Derivative Generation
→
VEGFR2 Active Site Prediction & Receptor Prep
→
Molecular Docking & Interaction Studies
→
ADMET & Toxicity Profiling
→
Pharmacophore & DFT Analysis
→
Molecular Dynamics Simulation
→
Binding Free Energy Calculation (MM/GBSA, MM/PBSA)
→
Lead Candidate Prioritization
| ADMET Property | AI-Fragmented Lead (Derivative 7) | Sorafenib (Reference) |
|---|---|---|
| Binding Affinity (kcal/mol) | -11.7 | -10.2 |
| Hepatotoxicity Risk (DILI) | Safe (Probability: 0.39) | Toxic (Probability: 0.591) |
| Aqueous Solubility (Log S ESOL) | Poorly soluble (approx. -4.85) | Poorly soluble (approx. -5.11) |
| Lipophilicity (Log Po/w) | 3.72 (More balanced) | 4.10 |
| Drug-Likeness (Lipinski violations) | 0 violations | 0 violations |
| HOMO-LUMO Gap (a.u.) | 0.15433 (Narrower, higher polarizability) | 0.16219 |
Case Study: Unprecedented Stability & Drug-like Properties via AI
The AI-driven optimization not only improved binding affinity but also yielded a lead candidate with exceptional stability under dynamic physiological conditions. Molecular dynamics simulations, spanning 500 nanoseconds, confirmed that Derivative 7 maintains a stable binding mode with VEGFR2, characterized by consistent RMSD values, robust hydrogen bonding, and preserved protein compactness. This level of stability, combined with the favorable ADMET profile—especially the reduced hepatotoxicity risk—positions Derivative 7 as a significantly improved and safer therapeutic candidate compared to its parent compound, Sorafenib. This demonstrates the critical role of AI in moving beyond traditional drug design to create compounds that are not only potent but also inherently more stable and drug-like.
Calculate Your AI-Driven R&D ROI
Estimate the potential cost savings and efficiency gains your organization could achieve by integrating AI into your drug discovery and optimization processes.
Estimated Annual Cost Savings
Annual Hours Reclaimed
Your AI Implementation Roadmap
A structured approach to integrating AI into your drug discovery workflow, ensuring seamless transition and maximized impact.
Phase 1: Discovery & Strategy
Initial consultation to understand your current R&D processes, identify key pain points, and define strategic objectives for AI integration. This includes data assessment and feasibility studies.
Phase 2: AI Model Development & Customization
Development or adaptation of AI models tailored to your specific research needs, such as predictive models for compound screening, ADMET prediction, or molecular dynamics simulations.
Phase 3: Integration & Training
Seamless integration of AI tools with existing R&D platforms. Comprehensive training for your scientific teams to ensure proficiency and adoption of new AI-powered workflows.
Phase 4: Optimization & Scaling
Continuous monitoring, evaluation, and refinement of AI models based on performance metrics. Scaling AI solutions across different research projects and departments to maximize impact.
Ready to Transform Your Drug Discovery?
Leverage cutting-edge AI to accelerate your R&D, discover superior drug candidates, and reduce time-to-market. Our experts are ready to build a bespoke strategy for your enterprise.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat